ACRV Company Profile and Key Details

Q: Who are the executives of ACRV?

Ms. Katharine Peterson CPAVice President of Fin. & AccountingMs. Kristina Masson Ph.D.Co-Founder, Executive Vice President of Bus. Operations, Treasurer, Sec. & DirectorDr. Adam D. Levy M.B.A., Ph.D.Senior Vice President and Head of Investor Relations & Corporation AffairsMs. Crystal MercadoGlobal Head of HRMr. Bruce CloseVice President of Quality & ComplianceDr. Eric J. Devroe Ph.D.Chief Operating OfficerMr. Rasmus Holm-JorgensenChief Financial OfficerMs. Mary-Alice Miller J.D.Gen. CounselMr. Joon Jung Ph.D.Vice President & Head of Data ScienceMr. Erick Gamelin M.D., Ph.D.Chief Medical OfficerDr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory BoardDr. Peter Blume-Jensen M.D., Ph.D.Co-Founder, Chairman, Chief Executive Officer, Pres & Acting Chief Scientific OfficerMs. Parvin MiahVice President & Head of HRMs. Kristina Masson M.B.A., Ph.D.Co-Founder, Executive Vice President of Bus. Operations, Site Head, Treasurer, Sec. & Director

NASDAQ : ACRV

Acrivon Therapeutics Common Stock

$1.98

-0.04999996-2.46%

At Close 4:00 PM

$2.07

+0.09+4.55%

After-Market 08:30 PM

57.29

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Acrivon Therapeutics, Inc. Common Stock (ACRV) stock declined over -2.46%, trading at $1.98 on NASDAQ, down from the previous close of $2.03. The stock opened at $2.04, fluctuating between $1.97 and $2.08 in the recent session.

Stock Snapshot

2.03

Prev. Close

62.48M

Market Cap

1.97

Day Low

-0.94

P/E Ratio

-2.11

EPS (TTM)

-1.97

Cash Flow per Share

2.04

Open

31.56M

Number of Shares

2.08

Day High

70.93%

Free Float in %

5.43

Book Value

540.58K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 08, 2026	2.04	2.08	1.97	1.98	540.56K
May 07, 2026	2.08	2.10	2.00	2.03	453.55K
May 06, 2026	2.11	2.14	2.04	2.09	422.78K
May 05, 2026	2.21	2.24	2.04	2.08	524.14K
May 04, 2026	2.09	2.21	2.05	2.17	1.14M
Apr 30, 2026	1.82	1.87	1.79	1.85	352.85K
Apr 29, 2026	1.91	1.91	1.78	1.81	327.64K
Apr 28, 2026	1.87	1.97	1.87	1.90	489.47K
Apr 27, 2026	1.89	1.97	1.79	1.88	877.68K
Apr 23, 2026	1.98	2.00	1.85	1.89	520.8K
Apr 22, 2026	1.79	2.02	1.77	1.97	6.13M
Apr 21, 2026	1.85	1.87	1.75	1.76	508.63K
Apr 20, 2026	1.78	1.95	1.77	1.86	1.2M
Apr 17, 2026	1.70	1.79	1.70	1.78	585.13K
Apr 16, 2026	1.69	1.71	1.65	1.67	422.35K
Apr 14, 2026	1.61	1.69	1.60	1.64	334.53K
Apr 13, 2026	1.53	1.64	1.53	1.61	865.46K
Apr 10, 2026	1.53	1.61	1.51	1.56	415.09K
Apr 09, 2026	1.48	1.59	1.44	1.55	761.47K
Apr 08, 2026	1.56	1.58	1.46	1.53	500.38K

Contact Details

Watertown, MA 02472

United States

https://www.acrivon.com 617 207 8979

About Company

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Stock Peers

ARGX

-5.14-0.65%

argenx SE$782.17 REGN

5.79+0.82%

Regeneron Pharmaceuticals, Inc.$714.89 UTHR

-4.24-0.74%

United Therapeutics Corporation$564.94 MDGL

-24.82-4.64%

Madrigal Pharmaceuticals, Inc.$510.04 VRTX

4.82+1.13%

Vertex Pharmaceuticals Incorporated$429.82 PRAX

-3.26-0.98%

Praxis Precision Medicines, Inc.$330.02 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

9.01+3.04%

Krystal Biotech, Inc.$305.71 ALNY

-0.86-0.29%

Alnylam Pharmaceuticals, Inc.$295.05 ASND

-7.48-3.04%

Ascendis Pharma A/S$238.66

Company Overview

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) closed at $1.98 USD, losing -$0.05 (-2.46%) from the previous close of $2.03. The stock is currently mid-range between its 52-week high and low $1.05 and $3.56. With a market capitalization of about $62.48 million, Acrivon Therapeutics, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~2.02). Key stats such as the average daily volume over the past year has been around 820.97 thousand shares, volume is running light vs its 52-week average. Headquartered in Watertown, MA, Acrivon Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter Blume-Jensen, the company employs approximately 75 people and listed since November 15, 2022. Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.

Technical Performance

ACRV has shown sold momentum, gaining 20.25% over the past week and 8.29% over the past quarter, though year-to-date performance is down -18.67%. Short-term trend indicators are mixed aligned (SMA20 11.82%, SMA50 -6.74%, SMA200 8.24%). The stock’s 14-day RSI is 55.13 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.0% below its high and over 75.24% above its low. Average 10-day trading volume of 537.13 thousand shares is below the 3-month average of 821.74 thousand, indicating normal recent market interest.

Valuation Metrics

Acrivon Therapeutics, Inc. Common Stock trades at a P/E ratio of -0.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.68 suggesting the stock is closer to book value. The P/FCF stands at -0.96, also below market averages.

Dividend & Fair Value

Acrivon Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.01. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Acrivon Therapeutics, Inc. Common Stock generated EPS of -$2.13 over the past year. Five-year average earnings growth is -74.96%. Wall Street analysts project EPS growth of 6.86% annually over the next five years. The latest quarter delivered EPS of -$0.49. The next quarter is forecast at -$0.48. Next year's EPS is expected at -$18.86. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $8.00. The high target offers 859.6% upside. The low target suggests 304.04% downside. The mean target is $11.00. This offers 455.56% upside. Acrivon Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended March 19, 2026, missed forecasts by 0.0%. The prior quarter beat by -17.54%. Over the last six quarters, Apple has recorded several small beats. These include 5.36% in November 13, 2024.

Shareholding & Insider Activity

Acrivon Therapeutics, Inc. Common Stock has 38.74 million shares outstanding. The public float is 21.79 million shares, elevated short interest at 12.48% of float. This equals 2.39 million shares. The short ratio is 3.9 days. Institutional investors hold 70.65% of the float. Insiders own 20.57%. RA CAPITAL MANAGEMENT, L.P. holds 4.38 million shares, Chione Ltd has 3.85 million shares and PERCEPTIVE ADVISORS LLC has 3.10 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Acrivon Therapeutics Common Stock has not generated any revenue. Returns are negative, with ROA at -43.68% and ROE at -49.83%.
On valuation metrics, Acrivon Therapeutics Common Stock trades at a P/E of -0.98, P/S of 0.00 and P/B of 0.68. The current ratio is 7.69 and quick ratio is 7.69. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -23.50.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Acrivon Therapeutics Common Stock posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $536.00K (margin 0.00%). Operating income was - $67.24M (margin 0.0%). Net income was- $60.39M (EPS - $2.74).
The company ended the quarter with $127.46M in cash and short-term investments, a total debt of $4.64M, and net debt of - $31.37M. Total assets were $138.27M, with equity of $121.20M. Financials further reflected weakness, with operating cash flow of - $42.64M, free cash flow of - $43.93M, and capital expenditures of - $1.29M.

Price Forecast & Outlook

Our AI price prediction model suggests that Acrivon Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.64%, with price expected at $2.25 by May 22, 2026, within a range of $2.15 to $2.36 3-Month Outlook: Projected rise of 297.47%, reaching $7.87 by August 06, 2026, with a range of $7.06 to $8.64. 1-Year Outlook: Projected gain of 281.82%, with price at $7.56 by May 07, 2027, within a range of $0.00 to $12.62.

Key Takeaways

Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) shares are down -18.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Acrivon Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.98. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $19.79, suggesting 899.49% upside. Our AI forecast model points to short-term strength (13.64% over two weeks), a medium-term rise (297.47% over three months), and a longer-term gain (281.82% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Acrivon Therapeutics, Inc. Common Stock (ACRV) stock price?

Acrivon Therapeutics, Inc. Common Stock (NASDAQ: ACRV) stock price is $1.98 in the last trading session. During the trading session, ACRV stock reached the peak price of $2.08 while $1.97 was the lowest point it dropped to. The percentage change in ACRV stock occurred in the recent session was -2.46% while the dollar amount for the price change in ACRV stock was - $0.05.

ACRV's industry and sector of operation?

The NASDAQ listed ACRV is part of Biotechnology industry that operates in the broader Healthcare sector. Acrivon Therapeutics, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACRV?

Ms. Katharine Peterson CPA
Vice President of Fin. & Accounting
Ms. Kristina Masson Ph.D.
Co-Founder, Executive Vice President of Bus. Operations, Treasurer, Sec. & Director
Dr. Adam D. Levy M.B.A., Ph.D.
Senior Vice President and Head of Investor Relations & Corporation Affairs
Ms. Crystal Mercado
Global Head of HR
Mr. Bruce Close
Vice President of Quality & Compliance
Dr. Eric J. Devroe Ph.D.
Chief Operating Officer
Mr. Rasmus Holm-Jorgensen
Chief Financial Officer
Ms. Mary-Alice Miller J.D.
Gen. Counsel
Mr. Joon Jung Ph.D.
Vice President & Head of Data Science
Mr. Erick Gamelin M.D., Ph.D.
Chief Medical Officer
Dr. Jesper V. Olsen Ph.D.
Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Dr. Peter Blume-Jensen M.D., Ph.D.
Co-Founder, Chairman, Chief Executive Officer, Pres & Acting Chief Scientific Officer
Ms. Parvin Miah
Vice President & Head of HR
Ms. Kristina Masson M.B.A., Ph.D.
Co-Founder, Executive Vice President of Bus. Operations, Site Head, Treasurer, Sec. & Director

How ACRV did perform over past 52-week?

ACRV's closing price is 88.57% higher than its 52-week low of $1.05 where as its distance from 52-week high of $3.56 is -44.38%.

How many employees does ACRV have?

Number of ACRV employees currently stands at 75.

Link for ACRV official website?

Official Website of ACRV is: https://www.acrivon.com

How do I contact ACRV?

ACRV could be contacted at phone 617 207 8979 and can also be accessed through its website. ACRV operates from 480 Arsenal Way, Watertown, MA 02472, United States.

How many shares of ACRV are traded daily?

ACRV stock volume for the day was 540.58K shares. The average number of ACRV shares traded daily for last 3 months was 820.97K.

What is the market cap of ACRV currently?

The market value of ACRV currently stands at $62.48M with its latest stock price at $1.98 and 31.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	75
Beta	1.74
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ACRV Company Profile and Key Details

Acrivon Therapeutics Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook